var data={"title":"Dalbavancin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Dalbavancin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/736950?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=dalbavancin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Dalbavancin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25184320\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Dalvance</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24932710\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Glycopeptide</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25334663\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\"> <b>Acute bacterial skin and skin structure infections</b>: IV: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Single-dose regimen:</i> 1,500 mg as a single dose </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Two-dose regimen:</i> 1,000 mg as a single dose initially, followed by 500 mg as a single dose 1 week later</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25334664\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25334665\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &ge;30 mL/minute:  No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &lt;30 mL/minute (not on regularly scheduled dialysis):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Single-dose regimen:</i> 1,125 mg as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Two-dose regimen:</i> 750 mg as a single dose initially, followed by 375 mg as a single dose 1 week later.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ESRD patients receiving intermittent hemodialysis (IHD) (regularly scheduled): No dosage adjustment necessary; administer without regard to timing of hemodialysis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25334666\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild impairment (Child-Pugh class A): No dosage adjustment necessary. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Moderate or severe impairment (Child-Pugh class B or C):  There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied); use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25184321\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dalvance: 500 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25184319\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25334668\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Infuse over 30 minutes. If a common IV line is being used to administer other drugs in addition to dalbavancin, the line should be flushed before and after each infusion with D5W.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25334671\" class=\"block uica drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Adult</span>\n    <p style=\"text-indent:0em;\">\n      <i>IV infusion:</i> 500 to 1,500 mg in 100 to 1,500 mL (concentration of 1 to 5 mg/mL) of D5W. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24932711\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Acute bacterial skin and skin structure infections:</b> Treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following gram-positive microorganisms: <i>Staphylococcus aureus</i> (including methicillin-susceptible and methicillin-resistant strains), <i>Streptococcus pyogenes</i>, <i>Streptococcus agalactiae</i>, <i>S. dysgalactiae</i>, <i>Streptococcus anginosus</i> group (including <i>S. anginosus</i>, <i>S. intermedius</i>, <i>S. constellatus</i>), and <i>Enterococcus faecalis</i> (vancomycin-susceptible strains)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25184036\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Flushing (&lt;2%), phlebitis (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (5%), dizziness (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (3%), pruritus (2%), urticaria (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypoglycemia (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (6%), diarrhea (4%), vomiting (3%), abdominal pain (&lt;2%), gastrointestinal hemorrhage (&lt;2%), hematochezia (&lt;2%), melena (&lt;2%), oral candidiasis (&lt;2%), pseudomembranous colitis (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Acute posthemorrhagic anemia (&lt;2%), anemia (&lt;2%), eosinophilia (&lt;2%), hematoma (spontaneous; &lt;2%), increased INR (&lt;2%), leukopenia (&lt;2%), neutropenia (&lt;2%), petechia (&lt;2%), thrombocythemia (&lt;2%), thrombocytopenia (&lt;2%), wound hemorrhage (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Hepatotoxicity (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum alkaline phosphatase (&lt;2%), increased serum transaminases (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Anaphylactoid reaction (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Vulvovaginal infection (mycotic; &lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Bronchospasm (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Infusion related reaction (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Anaphylaxis, <i>Clostridium difficile</i>-associated diarrhea, hypersensitivity reaction, increased serum ALT (&gt;3 x ULN)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24932712\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to dalbavancin or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25334262\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic effects: Patients with normal baseline transaminase levels may have ALT elevation &gt;3 times the upper limit of normal (ULN) during therapy; in clinical studies, abnormalities in liver tests (ALT, AST, bilirubin) were reported with similar frequency in the dalbavancin and comparator arms.  ALT elevations were reversible after discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Serious hypersensitivity (anaphylactic) and skin reactions have been reported with dalbavancin. Discontinue treatment if an allergic reaction occurs. Dalbavancin cross-sensitivity to other glycopeptides may occur; exercise caution in patients with a history of glycopeptide allergy; carefully screen for previous hypersensitivity reactions to glycopeptides prior to administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infusion reactions: Rapid intravenous infusions of dalbavancin (&lt;30 minutes)  may cause reactions that resemble &ldquo;Red-Man Syndrome,&rdquo; (eg, flushing of the upper body, urticaria, pruritus, rash). Stopping or slowing the infusion may result in cessation of these reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Superinfection: Use may result in fungal or bacterial superinfection, including <i>Clostridium difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with moderate to severe hepatic impairment (Child-Pugh class B or C).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24958077\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24958074\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=95502&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25334259\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. The long half-life of dalbavancin should be considered when evaluating potential exposure to the fetus.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25334261\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if dalbavancin is excreted into breast milk. The manufacturer recommends that caution be exercised when administering to nursing women. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25334672\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Baseline BUN, serum creatinine, and liver function tests (AST, ALT, bilirubin). Monitor patients for any infusion-related reactions and for superinfection during therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25334409\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Dalbavancin is a lipoglycopeptide which binds to the D-alanyl-D-alanine terminus of the stem pentapeptide in nascent cell wall peptidoglycan, preventing cross-linking and interfering with cell wall synthesis. It is bactericidal in vitro against <i>Staphylococcus aureus</i> and <i>Streptococcus pyogenes</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25334544\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: 7 to 13 L (Leighton, 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 93% (primarily to albumin)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Minor metabolite (hydroxy-dalbavancin)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 346 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (33% as unchanged drug, 12% as hydroxy metabolite); feces (20%) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25211462\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Dalvance Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (1): $1,841.64</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46047359\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Xydalba (CZ, DK, EE, ES, FR, HR, HU, IE, LT, PL, PT, RO, SI, SK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW.  Once-weekly dalbavancin versus daily conventional therapy for skin infection. <i>N Engl J Med</i>. 2014;370(23):2169-2179.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dalbavancin-drug-information/abstract-text/24897082/pubmed\" target=\"_blank\" id=\"24897082\">24897082</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dalvance (dalbavancin) [prescribing information]. Parsippany, NJ: Durata Therapeutics; January 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jauregui LE, Babazadeh S, Seltzer E, et al.  Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections.  <i>Clin Infect Dis</i>. 2005;41(10):1407-1415.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dalbavancin-drug-information/abstract-text/16231250/pubmed\" target=\"_blank\" id=\"16231250\">16231250</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leighton A, Gottlieb AB, Dorr MB, et al.  Tolerability, pharmacokinetics and serum bactericidal activity of intravenous dalbavancin in healthy volunteers.  <i>Antimicrob Agents Chemother</i>. 2004;48(3):940-945.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dalbavancin-drug-information/abstract-text/14982787/pubmed\" target=\"_blank\" id=\"14982787\">14982787</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Raad I, Darouiche R, Vazquez J, et al.  Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens.  <i>Clin Infect Dis</i>. 2005;40(3):374-380.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dalbavancin-drug-information/abstract-text/15668859/pubmed\" target=\"_blank\" id=\"15668859\">15668859</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Seltzer E, Dorr MB, Goldstein BP, Perry M, Dowell JA, Henkel T; Dalbavancin Skin and Soft-Tissue Infection Study Group. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections.  <i>Clin Infect Dis</i>. 2003;37(10):1298-1303.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dalbavancin-drug-information/abstract-text/14583862/pubmed\" target=\"_blank\" id=\"14583862\">14583862</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 95502 Version 56.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F25184320\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F24932710\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F25334663\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F25334664\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F25334665\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F25334666\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F25184321\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F25184319\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F25334668\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Adult\" href=\"#F25334671\" class=\"outlineLink\">Usual Infusion Concentrations: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F24932711\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F25184036\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F24932712\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F25334262\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F24958077\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F24958074\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F25334259\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F25334261\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F25334672\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F25334409\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F25334544\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F25211462\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F46047359\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/95502|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=dalbavancin-patient-drug-information\" class=\"drug drug_patient\">Dalbavancin: Patient drug information</a></li></ul></div></div>","javascript":null}